Evidence for granulocyte activation by OKT3.
Schmaldienst
S
S
Institute of Immunology, University of Vienna, Austria.
Böhmig
G
G
Pohanka
E
E
Kovarik
J
J
Zlabinger
G J
GJ
D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D016030:Kidney Transplantation / Q000276:immunology*; D007781:Lactoferrin / Q000097:blood; D016177:Macrophage-1 Antigen / Q000032:analysis; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D016177:Macrophage-1 Antigen; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D007781:Lactoferrin